First Tracks Biotherapeutics, Inc.
TRAX evidence brief
What we can confirm
- BioSniper Score:
- 7.9 / 10
- Market Cap:
- $1.30B
- Lead Asset:
- anb033
What it means
What to watch
Prepared research question
What matters most for TRAX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TRAX
First Tracks Biotherapeutics, Inc. (TRAX) is a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways in autoimmune and inflammatory diseases, with a lead program ANB033 (CD122 antagonist) in celiac disease and eosinophilic esophagitis.
Key risk: No approved products
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$1.30B
Cash Runway
—
Lead Asset
anb033
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates for First Tracks Biotherapeutics, Inc..
Similar companies
First Tracks Biotherapeutics, Inc. (TRAX) is a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways in autoimmune and inflammatory diseases, with a lead program ANB033 (CD122 antagonist) in celiac disease and eosinophilic esophagitis.
- First Tracks launched on Nasdaq on April 20, 2026 with $180 million in cash and a two-year cash runway [news · 2026-04-20].
- As of June 30, 2026, the company reported cash & equivalents of $168.0M, net income of -$33.4M, and shareholders' equity of $168.8M [sec].
- ANB033, a CD122 antagonist, is in Phase 1b trials for celiac disease and eosinophilic esophagitis; the U.S. FDA granted Fast Track designation for ANB033 in celiac disease [news · 2026-08-12].
- Pipeline includes rosnilimab (pathogenic T cell depleter) for rheumatoid arthritis, with 7 competitors listed [pipeline].
- First Tracks was spun off from AnaptysBio, which now manages financial collaborations for Jemperli and imsidolimab [news · 2026-05-12].
What works
- Cash position of $168.0M as of June 30, 2026 provides a multi-year runway to advance clinical programs [sec].
- ANB033 received U.S. FDA Fast Track designation for celiac disease, which may expedite development and review [news · 2026-08-12].
- The company has a clear near-term data catalyst: top-line Cohort 1 data for ANB033 in celiac disease expected in Q4 2026 [news · 2026-08-12].
What to weigh
- The company reported a net loss of $33.4M for the six months ended June 30, 2026, indicating significant operating expenses relative to revenue [sec].
- ANB033 is still in Phase 1b; no approved products or late-stage pivotal data exist yet, so clinical and regulatory risk remains high [pipeline].
- The rheumatoid arthritis program rosnilimab faces a competitive landscape with at least 7 competitors, including Phase 3 programs from Novartis and Janssen [pipeline].
From the filings
Quoted directly from source documents.
First Tracks launched with $180M cash and two-year runway
“First Tracks Biotherapeutics launches with $180 million in cash and two-year cash-runway”
News · April 20, 2026
ANB033 received Fast Track designation from FDA for celiac disease
“U.S. FDA granted Fast Track designation for ANB033 for the treatment of CeD”
News · August 12, 2026
Top-line Cohort 1 data for ANB033 expected in Q4 2026
“top-line Cohort 1 data reaffirmed for Q4 2026”
News · August 12, 2026
Risks & what to watch (4)›
Key risks
- No approved products — All programs are preclinical or Phase 1; no marketed drugs generate revenue, increasing reliance on financing [pipeline].
- Net loss of $33.4M — For six months ended June 30, 2026, net loss was $33.4M, indicating high cash burn [sec].
- Competitive rheumatoid arthritis space — Rosnilimab faces 7 competitors, including Phase 3 programs from Novartis and Janssen [pipeline].
- Early-stage clinical data only — ANB033 Phase 1b data not yet released; efficacy and safety remain unproven [news · 2026-08-12].
What to watch
- Top-line Cohort 1 data from ANB033 Phase 1b celiac disease trial expected in Q4 2026 [news · 2026-08-12].
- Top-line Cohort 2 data from ANB033 Phase 1b celiac disease trial anticipated in Q1 2027 [news · 2026-08-12].
- Enrollment progress and updates for ANB033 Phase 1b in eosinophilic esophagitis [pipeline].
- Cash runway and burn rate updates in subsequent quarterly financial reports [sec].
Sources: Competitor trials · News · Pipeline · Generated October 13, 2026 · How we verify sources →
Run First Tracks Biotherapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available First Tracks Biotherapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.09 · 0% dilution
No tracked pipeline phase
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for First Tracks Biotherapeutics, Inc.?
First Tracks Biotherapeutics, Inc. (TRAX) is a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways in autoimmune and inflammatory diseases, with a lead program ANB033 (CD122 antagonist) in celiac disease and eosinophilic esophagitis.
Who is the CEO of First Tracks Biotherapeutics, Inc.?
Mr. Daniel R. Faga is the chief executive officer of First Tracks Biotherapeutics, Inc. (TRAX).
Where is First Tracks Biotherapeutics, Inc. headquartered?
First Tracks Biotherapeutics, Inc. (TRAX) is headquartered in San Diego, CA, United States.
What therapeutic areas does First Tracks Biotherapeutics, Inc. focus on?
First Tracks Biotherapeutics, Inc. develops therapies across Immunology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.